Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Sixtyfour CEO Saarth Shah explains how his company built AI research agents around rigorous evaluation systems rather than language model fluency, creating verification infrastructure that proves ...

The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about ...

GigaWiper is a destructive backdoor that combines multiple wiping and ransomware-like capabilities into a single operational ...

On July 4, 2026, Vitalik Buterin published the most consequential Ethereum protocol document in four years: an updated "Lean Ethereum" strawmap that commits the world's second-largest blockchain to ...

A decision tree regression system incorporates a set of if-then rules to predict a single numeric value. Decision tree regression is rarely used by itself because it overfits the training data, and so ...

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...

Ask the publishers to restore access to 500,000+ books. An icon used to represent a menu that can be toggled by interacting with this icon. A line drawing of the Internet Archive headquarters building ...